Assessment of the genotoxic potential of a migraine-specific drug by comet and cytokinesis-block micronucleus assays


ÇAYIR A. , ÇOBANOĞLU H. , Coskun M.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol.16, no.5, pp.441-446, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 5
  • Publication Date: 2020
  • Doi Number: 10.1080/17425255.2020.1748598
  • Title of Journal : EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
  • Page Numbers: pp.441-446

Abstract

Background: Eletriptan is a migraine-specific drug-containing the triptan group. In terms of drug safety, the present study aimed to investigate the genotoxic potential of eletriptan. Research design & methods: We conducted our study by using the cytokinesis-block micronucleus cytome (CBMN) assay, a comprehensive method for measuring micronucleus formation, and a sensitive method for detecting DNA-strand breaks. In the assay, cytokinesis-block proliferation index and the frequency of micronuclei were evaluated in lymphocytes treated with three different concentrations (1, 10 and 25 mu g/ml) of eletriptan for 48 hours. In comet assays, DNA damage was evaluated in leucocytes treated with three different concentrations (1, 10 and 25 mu g/ml) of eletriptan for an hour. Results: Eletriptan did not induce cytotoxicity nor any increased micronuclei frequencies. While the comet parameters % DNA in tail, tail moment, and the olive moment was found to be significantly increased at 10 and 25 mu g/ml, the cytokinesis-block proliferation index values were not. Conclusion: These findings suggest that eletriptan is non-cytotoxic but potentially weakly genotoxic at higher concentrations (10 and 25 mu g/ml).